1259 results for 'erbb her'

Quick Facts About TigatuzumabWhat is Tigatuzumab?Tigatuzumab is a monoclonal antibody that targets the death receptor 5 (DR5) pathway, inducing apoptosis in cancer cells.What is the mech

Quick Facts About NaratuximabWhat is Naratuximab?Naratuximab is an anti-CD37 monoclonal antibody-drug conjugate (ADC) designed to target B-cell malignancies, particularly non-Hodgkin lym

What You Need to Know About DupilumabWhat is Dupilumab?Dupilumab is a fully human monoclonal antibody designed to treat various chronic inflammatory diseases by inhibiting key cytokines

Introduction to PD-1, PD-L1, and PD-L2 in Cancer ImmunotherapyThe PD-1/PD-L1 immune checkpoint pathway has been instrumental in cancer immunotherapy, with PD-1 (programmed death-1) inhibi

Quick Facts About RagifilimabWhat is Ragifilimab?Ragifilimab is an investigational anti-CD47 monoclonal antibody developed to block the CD47-SIRPα interaction, thereby enhancing macropha

What You Need to Know About MilatuzumabWhat is Milatuzumab?Milatuzumab is a humanized monoclonal antibody targeting CD74, a molecule involved in antigen presentation and cell signaling.W

Cancer immunotherapy has revolutionized the treatment landscape for various malignancies. One of the most promising therapeutic strategies is the use of immune checkpoint inhibitors, part

Lymphocyte Activation Gene-3 (LAG-3) is an immune checkpoint receptor that plays a critical role in regulating T cell function. In recent years, LAG-3 has emerged as a potential target fo

Introduction to CD122 in Immunotherapy CD122, also known as the interleukin-2 receptor beta chain (IL-2Rβ), is a critical component of the immune system's response to pathogens and malign

Quick Facts About MurlentamabWhat is Murlentamab?Murlentamab is a novel monoclonal antibody designed to target CD47, a "don’t eat me" signal that helps cancer cells evade the immune syst

Quick Facts About LabetuzumabWhat is Labetuzumab?Labetuzumab is a monoclonal antibody targeting CEACAM5, a protein overexpressed in various cancers, primarily colorectal carcinoma.How do

What You Need to Know About CabiralizumabWhat is Cabiralizumab?Cabiralizumab is a monoclonal antibody targeting the colony-stimulating factor-1 receptor (CSF1R), developed for treating c

Quick Facts About AvdoralimabWhat is Avdoralimab?Avdoralimab is a monoclonal antibody targeting C5aR1, playing a crucial role in modulating immune response and inflammation.What is the m

Quick Facts About TinurilimabWhat is Tinurilimab?Tinurilimab is a monoclonal antibody targeting CD47, a protein that cancer cells use to evade immune system attack. By blocking CD47, Tin

Quick Facts About AnifrolumabWhat is Anifrolumab?Anifrolumab is a monoclonal antibody that targets the type I interferon receptor, playing a crucial role in treating systemic lupus eryth

What You Need to Know About PolatuzumabWhat is Polatuzumab??Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b, a component of the B-cell receptor, used primarily in B-cel

A New Dawn in Cancer Treatment: Reprogramming the Immune System's Own Soldiers For decades, the fight against cancer has been a relentless battle of attrition, with treatments like chemotherapy and r

Pancreatic cancer survival rates Despite recent advances in our understanding of this disease, pancreatic cancer is one of the world’s most lethal malignan

Novel Gene Therapies for Cystic Fibrosis Cystic Fibrosis Cystic fibrosis (CF) is an autosomal recessive, life-limiting disease resulting from gene mutations that encode the cystic fibr

The advent of immune checkpoint targeting marks a significant milestone in the oncological field, offering a beacon of hope for patients battling cancer. This innovative approach leverages the bod